AtaGenix Laboratories
AtaGenix Laboratories
Are long timelines, inconsistent results, and low yields slowing down your monoclonal antibody development? AtaGenix accelerates your journey with our advanced Verified In-Situ Plate Seeding (VIPS™) technology, cutting development time by over 50% while ensuring clonality reports critical for IND submission. Our IP-free, royalty-free cell lines are designed for stability and high productivity, achieving yields exceeding 7g/L. With decades of expertise and a track record of generating 100+ stable cell lines, we provide a robust platform optimized for developability. Boost your research and bioproduction with AtaGenix’s innovative solutions.
AtaGenix streamlines stable cell line generation with high-efficiency solutions for biopharmaceutical development. Using VIPS™ technology (optional), we accelerate projects by 50%, ensuring monoclonality with high-resolution imaging. Our process delivers yields exceeding 7g/L, supporting long-term stability. We offer XtenCHOTM IP-free cell line, HEK293 and developability-focused testing to minimize production risks. With 15+ years of expertise, 5000+ de novo monoclonal antibodies developed, and 100+ stable cell lines generated, we ensure a seamless transfer to scale up production.
Accelerate cell line projects by over 50% with real-time, high-resolution imaging confirming monoclonality using VIPS™ technology.
Secure your investments with stable cell line development services achieving yields exceeding 7g/L.
Access royalty-free cell lines such as CHO-1, CHO-S, CHO-DG44, HEK293, or your preferred choice.
Reduce production risks with extensive early testing of antibody candidates.
Fast cell line and protocol transfer to CMO partners for cGMP bioproduction.
500+ monoclonal antibodies developed, 100+ stable cell lines generated, 28+ years of expertise.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
